Medtronic plc MDT 69.76
Health Care · NYSE · Data as of 2026-09-14
Medtronic plc (MDT) has delivered +1.9% annualized revenue growth, +1.8% earnings growth, and +5.4% dividend growth over 10 years of data. Ranked #268 of 1968 stocks overall and #28 of 260 in the Health Care sector by Steady Score.
About Medtronic plc
Company Overview
Medtronic develops medical devices and therapies used in hospitals and clinics worldwide. Its products include cardiac pacemakers and defibrillators, surgical instruments, insulin-delivery systems, neurostimulation devices and technologies for vascular, gastrointestinal and spinal procedures. Physicians use these products to diagnose, monitor and treat chronic disease and to perform surgery, while patients may rely on implanted or wearable devices for years.
Read more
Business Model & Revenue
Revenue comes from device sales, procedure-related consumables, implants and selected service and supply arrangements. Cardiovascular, Neuroscience, Medical Surgical and Diabetes are the main portfolios. Procedure volumes, hospital capital budgets, new product approvals and reimbursement drive demand. A large installed base can create replacement and consumable sales, while research, clinical trials and quality systems require substantial continuing investment.
Key Facts & Market Position
Medtronic spans many clinical specialties and combines durable capital equipment with implants and recurring supplies. Devices must meet stringent regulation and demonstrate safety and effectiveness, and product recalls can carry significant consequences. Global scale supports physician training and distribution, while innovation cycles, hospital purchasing power and competing therapies shape adoption.